Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...
Likosar stated, "We now expect total revenue of between $5.075 billion and $5.175 billion, with the midpoint consistent with our original guidance." Adjusted EPS is now expected in the range of $0.85 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results